Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

5.59USD
3:59pm EST
Change (% chg)

$0.06 (+1.08%)
Prev Close
$5.53
Open
$5.51
Day's High
$5.64
Day's Low
$5.51
Volume
90,556
Avg. Vol
265,771
52-wk High
$11.71
52-wk Low
$4.61

Latest Key Developments (Source: Significant Developments)

Progenics Pharmaceuticals Q3 loss per share $0.22
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals announces third quarter 2017 financial results and business update.Q3 loss per share $0.22.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.Progenics Pharmaceuticals Inc - ‍Q3 revenue totaled $2.7 million, down from $53.9 million in Q3 of 2016​.Progenics - ‍ended Q3 with cash and cash equivalents of $98.3 million, decrease of $40.6 million versus cash and cash equivalents as of December 31, 2016​.  Full Article

Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra
Thursday, 31 Aug 2017 04:05pm EDT 

Aug 31 (Reuters) - Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra.Progenics - co was notified that commercial drug product manufacturing facility for Azedra needs more time to prepare for pre-approval inspection by FDA.Progenics Pharma - ‍data from pivotal phase 2b study of azedra will be presented at 5th International Symposium On Pheochromocytoma & Paraganglioma on Sept. 1.Progenics - ‍under rolling submission, co has submitted all portions of NDA to FDA, except for notification of pre-approval inspection readiness​.Progenics Pharmaceuticals Inc - ‍interactions with FDA on Azedra rolling submission continue to be "positive and productive"​.Progenics Pharmaceuticals - ‍manufacturer has indicated it will need up to a few months to complete preparation for pre-approval inspection​ by FDA.  Full Article

Progenics Pharmaceuticals Q2 loss per share $0.24
Wednesday, 9 Aug 2017 07:30am EDT 

Aug 9 (Reuters) - Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals announces second quarter 2017 financial results and business update.Q2 loss per share $0.24.Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Progenics Pharmaceuticals Inc - qtrly ‍total revenues $2.8 million versus $8.5 million​.Azedra NDA expected to be submitted August 2017.Q2 revenue view $3.7 million -- Thomson Reuters I/B/E/S.  Full Article

Progenics Pharmaceuticals reports Q1 loss per share $0.23
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Progenics Pharmaceuticals Inc : :Progenics pharmaceuticals announces first quarter 2017 financial results and business update.Q1 loss per share $0.23.Q1 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Progenics Pharmaceuticals Inc - company on track to submit NDA in mid-2017 for Azedra.Progenics pharmaceuticals inc - Q1 revenue totaled $2.3 million, down from $2.5 million in q1 of 2016.Q1 revenue view $4.5 million -- Thomson Reuters I/B/E/S.Progenics Pharmaceuticals Inc - ended quarter with cash and cash equivalents of $126.3 million, a sequential decrease of $12.6 million.  Full Article

Progenics Pharmaceuticals posts Q4 loss per share $0.10
Thursday, 9 Mar 2017 07:30am EST 

Progenics Pharmaceuticals Inc : Progenics Pharmaceuticals announces fourth quarter and full-year 2016 financial results and business update .Q4 loss per share $0.10.  Full Article

Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment
Tuesday, 14 Feb 2017 07:00am EST 

Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals announces initiation of a phase 1 clinical trial of its PSMA-targeted therapeutic candidate 1095 for the treatment of metastatic prostate cancer.  Full Article

Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald
Monday, 9 Jan 2017 06:06am EST 

Progenics Pharmaceuticals Inc :Entered controlled equity offering sales agreement with Cantor Fitzgerald, pursuant to which Co may offer, sell up to $75 million stock.  Full Article

Progenics Pharma says 190 of 450 patients enrolled in phase 3 SPECT/CT imaging agent trial
Thursday, 22 Dec 2016 04:15pm EST 

Progenics Pharmaceuticals Inc : Progenics Pharmaceuticals Inc says approximately 190 of a planned 450 patients have been enrolled in trial to date . Progenics Pharmaceuticals announces independent committee’s positive recommendation for continuation of phase 3 clinical trial of SPECT/CT imaging agent 1404 .Progenics Pharmaceuticals announces independent committee’s positive recommendation for continuation of phase 3 clinical trial of SPECT/CT imaging agent 1404.  Full Article

Progenics Pharmaceuticals Q2 loss per share $0.08
Thursday, 4 Aug 2016 07:30am EDT 

Progenics Pharmaceuticals Inc : Q2 loss per share $0.08 . Progenics Pharmaceuticals announces second quarter 2016 financial and business results . Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S .On track to initiate phase 2/3 trial for PYL(TM) imaging agent and phase 1 trial for 1095 this year.  Full Article

Valeant and Progenics announce FDA approvals for relistor
Tuesday, 19 Jul 2016 06:04pm EDT 

Progenics Pharmaceuticals Inc : Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016 . Valeant and Progenics announce FDA approves relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain .FDA has approved relistor (methylnaltrexone bromide) tablets for treatment of opioid-induced constipation.  Full Article

BRIEF-Progenics Pharmaceuticals Q3 loss per share $0.22

* Progenics Pharmaceuticals announces third quarter 2017 financial results and business update